多重耐药病原体的威胁不断升级,需要采取创新的方法来对抗传染病。在这项研究中,我们检查了肽R23FS*,V31KS*,和R44KS*,它们被设计成包括源自金黄色葡萄球菌S1蛋白的淀粉样蛋白片段,以及一种或两种细胞穿透肽(CPP)成分。我们评估了这些肽在液体培养基中对革兰氏阳性细菌的各种菌株的抗微生物功效。包括金黄色葡萄球菌(209P和129B菌株),MRSA(SA180和ATCC43300株),和蜡状芽孢杆菌(菌株IP5832),和革兰氏阴性菌如铜绿假单胞菌(ATCC28753和2943菌株)和大肠杆菌(MG1655和K12菌株)。肽R23FS*,V31KS*,和R44KS*在24至48μM的浓度范围内对所有测试细菌表现出与庆大霉素和美罗培南相当的抗菌活性。这些肽对蜡状芽孢杆菌显示出更强的抗微生物作用。值得注意的是,与肽R23FS*和V31KS*相比,肽R44KS*显示出高功效,在较低的浓度下尤其明显,导致细菌生长的显著抑制。此外,与未修饰的肽V31KS和R44KS相比,修饰的肽V31KS*和R44KS*对不同菌株的细菌生长表现出增强的抑制作用。这些结果突出了整合细胞穿透肽的潜力,淀粉样蛋白片段,和氨基酸残基修饰,推进抗菌肽领域的创新,从而提高其对抗广谱病原体的效力。
The escalating threat of multidrug-resistant pathogens necessitates innovative approaches to combat infectious diseases. In this study, we examined peptides R23FS*, V31KS*, and R44KS*, which were engineered to include an amyloidogenic fragment sourced from the S1 protein of S. aureus, along with one or two cell-penetrating peptide (CPP) components. We assessed the antimicrobial efficacy of these peptides in a liquid medium against various strains of both Gram-positive bacteria, including S. aureus (209P and 129B strains), MRSA (SA 180 and ATCC 43300 strains), and B. cereus (strain IP 5832), and Gram-negative bacteria such as P. aeruginosa (ATCC 28753 and 2943 strains) and E. coli (MG1655 and K12 strains). Peptides R23FS*, V31KS*, and R44KS* exhibited antimicrobial activity comparable to gentamicin and meropenem against all tested bacteria at concentrations ranging from 24 to 48 μM. The peptides showed a stronger antimicrobial effect against B. cereus. Notably, peptide R44KS* displayed high efficacy compared to peptides R23FS* and V31KS*, particularly evident at lower concentrations, resulting in significant inhibition of bacterial growth. Furthermore, modified peptides V31KS* and R44KS* demonstrated enhanced inhibitory effects on bacterial growth across different strains compared to their unmodified counterparts V31KS and R44KS. These results highlight the potential of integrating cell-penetrating peptides, amyloidogenic fragments, and amino acid residue modifications to advance the innovation in the field of antimicrobial peptides, thereby increasing their effectiveness against a broad spectrum of pathogens.